JP2023540052A5 - - Google Patents
Info
- Publication number
- JP2023540052A5 JP2023540052A5 JP2023513671A JP2023513671A JP2023540052A5 JP 2023540052 A5 JP2023540052 A5 JP 2023540052A5 JP 2023513671 A JP2023513671 A JP 2023513671A JP 2023513671 A JP2023513671 A JP 2023513671A JP 2023540052 A5 JP2023540052 A5 JP 2023540052A5
- Authority
- JP
- Japan
- Prior art keywords
- target site
- mirna target
- mirna
- nucleic acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2013466.4 | 2020-08-27 | ||
| GBGB2013466.4A GB202013466D0 (en) | 2020-08-27 | 2020-08-27 | Genetic construct |
| PCT/PT2021/050028 WO2022045912A1 (en) | 2020-08-27 | 2021-08-25 | Genetic construct |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023540052A JP2023540052A (ja) | 2023-09-21 |
| JP2023540052A5 true JP2023540052A5 (enExample) | 2024-08-07 |
Family
ID=72749679
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023513671A Pending JP2023540052A (ja) | 2020-08-27 | 2021-08-25 | 遺伝子構築物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20230313229A1 (enExample) |
| EP (1) | EP4204572A1 (enExample) |
| JP (1) | JP2023540052A (enExample) |
| GB (1) | GB202013466D0 (enExample) |
| WO (1) | WO2022045912A1 (enExample) |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7041654B2 (en) * | 1997-10-03 | 2006-05-09 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Methods and compositions for inducing tumor-specific cytotoxicity |
| EP1199363A1 (en) * | 2000-10-20 | 2002-04-24 | Leadd B.V. | Phosphorylation modifications of apoptin |
| EP1661912A1 (en) * | 2004-11-29 | 2006-05-31 | Xigen S.A. | Fusion protein comprising a BH3-domain of a BH3-only protein |
| US9458509B2 (en) * | 2010-07-22 | 2016-10-04 | President And Fellows Of Harvard College | Multiple input biologic classifier circuits for cells |
| US20150182490A1 (en) * | 2012-06-26 | 2015-07-02 | Del Mar Pharmaceuticals | Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof |
| CN104017827A (zh) * | 2014-04-04 | 2014-09-03 | 天津医科大学总医院 | 一种慢病毒质粒表达载体及其构建方法和应用 |
| KR101607643B1 (ko) * | 2014-12-31 | 2016-03-30 | 한국원자력의학원 | Ｂａｘ/ｃｏｍｐｌｅｘ-Ⅰ 복합체를 이용한 암전이 억제제의 스크리닝 방법 |
| WO2019025800A1 (en) * | 2017-08-02 | 2019-02-07 | Autolus Limited | CELLS EXPRESSING A CHIMERIC ANTIGENIC RECEPTOR OR A MANIPULATED TCR AND COMPRISING A SELECTIVELY EXPRESSED SELECTIVE NUCLEOTIDE SEQUENCE |
| CN108676097B (zh) * | 2018-05-24 | 2020-01-14 | 北京肽和生物科技有限公司 | 一种靶向肿瘤细胞的嵌合肽或嵌合蛋白及其应用 |
| US11339395B2 (en) * | 2018-08-01 | 2022-05-24 | Massachusetts Institute Of Technology | RNA-based regulatory technologies for miRNA sensors |
| EP3874041A1 (en) * | 2018-11-01 | 2021-09-08 | Onconetics Pharmaceuticals, Inc. | Multi-component vector systems, methods of making, and uses thereof |
-
2020
- 2020-08-27 GB GBGB2013466.4A patent/GB202013466D0/en not_active Ceased
-
2021
- 2021-08-25 WO PCT/PT2021/050028 patent/WO2022045912A1/en not_active Ceased
- 2021-08-25 EP EP21772854.2A patent/EP4204572A1/en active Pending
- 2021-08-25 JP JP2023513671A patent/JP2023540052A/ja active Pending
- 2021-08-25 US US18/043,276 patent/US20230313229A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023544683A5 (enExample) | ||
| FI4211231T3 (fi) | Peptidimodifioitu aav-kapsidi | |
| US12291726B2 (en) | A549 host cells comprising a recombinant oncolytic adenovirus with modified E1A cancer-specific promoter | |
| JP2023506765A5 (enExample) | ||
| US12036247B2 (en) | Multiple transgene recombinant adenovirus | |
| JP2010516758A5 (enExample) | ||
| FI4536686T3 (fi) | Lihaksen parannetun transduktiotehokkuuden omaava peptidimodifioitu aav-kapsidi | |
| US20190352616A1 (en) | Multiple transgene recombinant adenovirus | |
| US20230242627A1 (en) | Composition and method for activating latent human immunodeficiency virus (hiv) | |
| JP2022066336A5 (enExample) | ||
| AU2018212017A1 (en) | Tumor selective TATA -box and CAAT-box mutants | |
| JP2023527083A5 (enExample) | ||
| JP2024535145A5 (enExample) | ||
| JP2024503091A5 (enExample) | ||
| JP2006523448A5 (enExample) | ||
| CN114773457B (zh) | 表达猪源性抗猪流行性腹泻病毒n蛋白单链抗体的重组腺病毒及其构建和用途 | |
| Bunte et al. | Inhibition of DNA binding of purified p55v‐myc in vitro by antibodies against bacterially expressed myc protein and a synthetic peptide. | |
| WO2020238427A1 (zh) | 特异杀伤肿瘤细胞的溶瘤病毒系统及其应用 | |
| JP2024507451A5 (enExample) | ||
| JP2024537797A5 (enExample) | ||
| JP2025503721A5 (enExample) | ||
| US7297535B2 (en) | Use of the human LRP/MVP promotor for a vector that can be induced by therapy | |
| TW202540418A (zh) | 新穎ｒｎａ構建體及使用其製備環狀ｒｎａ的方法 | |
| CN115491375A (zh) | 一种用于抑制alk表达的rna、基因线路及递送系统 | |
| Tjian | BINDING OF D2 PROTEIN TO SPECIFIC PAPOVAVIRUS SEQUENCES¹ |